Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.

Verena SailerHeidrun GevenslebenJoern DietrichDiane GoltzGlen KristiansenFriedrich BootzDimo Dietrich

Published in: PloS one (2017)

Using an independent analytical platform, PITX2 methylation was validated as a prognostic biomarker in HNSCC patients, identifying patients that potentially benefit from intensified surveillance and/or administration of adjuvant/neodjuvant treatment, i.e. immunotherapy.

Keyphrases

end stage renal disease
dna methylation
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
public health
prognostic factors
gene expression
genome wide
patient reported outcomes
mass spectrometry
patient reported